| ABUS Market Cap History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the ABUS market cap history going back to 11/15/2010:
Also see: ABUS Shares Outstanding History and ABUS YTD Return |
ABUS Market Cap History — Arbutus Biopharma Capitalization Over Time
As of 5/11/2026 Arbutus Biopharma has a market cap of 867.19 million. Investors often follow the ABUS market cap history to compare the size of the company over time.
This page shows ABUS market capitalization trends over time, with 58 market cap datapoints presented, dating back to 11/15/2010.
| ABUS Market Cap History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ABUS Historical Market Cap: +17.34% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ABUS Stock Price Chart |
| About Arbutus Biopharma Corp |
| Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. Co. is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. We show 58 historical shares outstanding datapoints in our ABUS shares outstanding history coverage, used to compute ABUS market cap on those dates. Understanding the changing numbers of shares outstanding, the changing share price, and the resulting changing ABUS market cap history over the course of time is important for investors interested in comparing ABUS's market cap history versus its peers. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies, and then calculating their respective market caps. Comparing the share price of ABUS versus a peer is one thing; comparing ABUS market cap versus a peer is a completely different story. Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares), the market cap for a company like ABUS can fluctuate over the course of history. With this page we aim to empower investors researching ABUS by allowing them to research the ABUS market cap history. |
| ABUS Current Stock Quote |
Quotes delayed 20 minutes  Free ABUS Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: The Importance of Market Cap | |
|
Video: The Importance of Market Cap
| ABUS Share Performance |
| Market Cap Peers |
| Arbutus Biopharma (ABUS) is categorized under the Miscellaneous sector; to help you further research historical market cap numbers, below are some other companies in the same sector:
ABX Market Cap History ACAB Market Cap History ACAC Market Cap History ACAH Market Cap History ACAM Market Cap History ACAQ Market Cap History ACAX Market Cap History ACB Market Cap History ACBA Market Cap History ACDI Market Cap History More Miscellaneous companies » |
ABUS Market Cap History | www.MarketCapHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in MarketCapHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
